GARP-TGF-β1 Monoclonal Antibody Clinical Trial Approved by FDA
On January 4, 2023, Shanghai Jiyu Pharmaceutical announced that the IND application for its Class 1 drug JYB1907, GARP-TGF-β1 monoclonal antibody i...
Read moreMaterialize your innovation
We are an innovative biotechnology company dedicated to providing high-quality proteins & enzymes that meet novel customer demands.
Facilities & equipment
→ R&D production headquarters of over 50,000 square feet
→ GMP-production facility of over 100,000 square feet
→ Scientific team of 200 researchers and production engineers
SAMS™ Technology Platform
→ Structure Aided Design and Multiplex Screening (SAMS)
→ Optimizes protein configuration and expression conditions
→ Bioactive proteins in multiple cell lines.
Quality Systems
→ High-purity and bioactive proteins
→ Extensive quality control testing, including activity testing
→ Optional GMP-grade material for commercial manufacturing
Custom Production
→ Scientific support for structure optimization specific to your application
→ Bulk material supply for research and process development
→ GMP-Grade material for clinical manufacturing
→ Equipment certification, batch records, etc. for regulatory filing
Transmembrane Protein VLPs
Transmembrane proteins are difficult to express in their natural 3D configuration. We use virus-like-particles (VLPs) derived from self-assembling viral capsid proteins to express transmembrane proteins in their natural conformation. VLPs are non-infectious and have high immunogenicity. Our line of VLP-displayed antigens can be used for antibody drug discovery of otherwise difficult targets.
What's new at KACTUS
Focus on hematoma target FLT3
About FLT3 Fms-like tyrosine kinase 3 (FLT3) is also known as CD135 (Cluster of differentiation antigen 135) and FLK2 (Fetal liver kinase-2). It is...
Read more